Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
网页Phase 2b trial tests AP01, inhaled pirfenidone, in progressive PF. Avalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF).
New prototype therapy may repair IPF lung scarring by …
网页2024年4月26日 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
Study: ENV-101 improves IPF lung function, reverses fibrosis
网页2024年6月7日 · ENV-101 improved lung function and reversed key signs of lung scarring in patients with IPF, according to data from a Phase 2a trial.
AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease ...
网页1 天前 · The results announced last week are from a placebo-controlled Phase 2a study that enrolled 71 IPF patients in China. Patients were randomly assigned to receive a 30 mg dose of the drug once daily ...
IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets …
网页4 天之前 · The FIBRONEER-IPF trial included 1177 participants with IPF across more than 30 countries. They were divided into 3 groups, taking a dose of nerandomilast 9 mg, nerandomilast 18 mg, or placebo twice daily. The primary end point was absolute change in FVC from baseline to week 52. 1. After 52 weeks, patients taking either dose of …
Insilico Medicine reports positive Phase IIa | EurekAlert!
网页5 天之前 · Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI. Positive results ...
Nerandomilast Shows Promise in Idiopathic Pulmonary Fibrosis Trial
网页6 天之前 · IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind ...
Newly Designed Molecule Is Promising Potential Therapy for …
网页2022年10月28日 · A team led by Kaminski used a newly designed molecule, called MRG-229, with potential therapeutic implications for IPF. The study is one of the first to use a microRNA mimic as a viable therapeutic in the lungs. The group published its findings October 17 in eBioMedicine.
Researchers identify new molecular target for idiopathic …
网页2021年3月10日 · Researchers have identified a new molecular target that could lead to new treatments for idiopathic pulmonary fibrosis (IPF), a deadly lung disease. IPF is characterized by severe scarring of the lungs, a condition called fibrosis, which makes it progressively difficult to breathe.
First patient enrolled in FIBRONEER™-IPF Phase III trial
网页Ridgefield, Conn. and Ingelheim, Germany, October 26, 2022 – Boehringer Ingelheim today announced that the first U.S. patient has enrolled in FIBRONEER ™ -IPF, a global Phase III trial evaluating BI 1015550, an investigational phosphodiesterase 4B (PDE4B) inhibitor, in people living with idiopathic pulmonary fibrosis (IPF).